Thalys Medical Technology Group SHSE:603716 Lagerbericht Finanzdaten des Unternehmens
Thalys Medical Technology Group Corporation
SHSE:603716 Lagerbericht
Marktkapitalisierung: CN¥1.6b
603716 Aktienübersicht Die Thalys Medical Technology Group Corporation bietet intensive Dienstleistungen im Bereich der medizinischen Inspektion in China an.
Risikoanalyse Alle Risikoprüfungen anzeigen Thalys Medical Technology Group Corporation Wettbewerber Preisentwicklung & Leistung
Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Thalys Medical Technology Group Historische Aktienkurse Aktueller Aktienkurs CN¥8.45 52-Wochen-Hoch CN¥13.10 52-Wochen-Tief CN¥5.13 Beta 0.76 11 Monat Veränderung 19.35% 3 Monate Veränderung 24.82% 1 Jahr Veränderung -28.21% 33 Jahre Veränderung -42.91% 5 Jahre Veränderung -50.61% Veränderung seit IPO -23.68%
Aktuelle Nachrichten und Updates
Third quarter 2024 earnings released: CN¥0.42 loss per share (vs CN¥0.033 loss in 3Q 2023) Oct 29
Wuhan Herun Ruihui Business Consulting Co., Ltd. agreed to acquire 80% stake in Wuhan Huixin Technology Development Co., Ltd. from Thalys Medical Technology Group Corporation (SHSE:603716) for CNY 72 million. Oct 02
Thalys Medical Technology Group Corporation to Report Q3, 2024 Results on Oct 29, 2024 Sep 30
Thalys Medical Technology Group Corporation (SHSE:603716) Surges 28% Yet Its Low P/S Is No Reason For Excitement Aug 12
Thalys Medical Technology Group Corporation to Report First Half, 2024 Results on Aug 30, 2024 Jun 28 Thalys Medical Technology Group Corporation (SHSE:603716) announces an Equity Buyback for CNY 20 million worth of its shares. Jun 06
Weitere Updates anzeigen
Third quarter 2024 earnings released: CN¥0.42 loss per share (vs CN¥0.033 loss in 3Q 2023) Oct 29
Wuhan Herun Ruihui Business Consulting Co., Ltd. agreed to acquire 80% stake in Wuhan Huixin Technology Development Co., Ltd. from Thalys Medical Technology Group Corporation (SHSE:603716) for CNY 72 million. Oct 02
Thalys Medical Technology Group Corporation to Report Q3, 2024 Results on Oct 29, 2024 Sep 30
Thalys Medical Technology Group Corporation (SHSE:603716) Surges 28% Yet Its Low P/S Is No Reason For Excitement Aug 12
Thalys Medical Technology Group Corporation to Report First Half, 2024 Results on Aug 30, 2024 Jun 28 Thalys Medical Technology Group Corporation (SHSE:603716) announces an Equity Buyback for CNY 20 million worth of its shares. Jun 06
Thalys Medical Technology Group Corporation, Annual General Meeting, May 20, 2024 Apr 29
First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.07 loss in 1Q 2023) Apr 28
Thalys Medical Technology Group Corporation, Annual General Meeting, May 20, 2024 Apr 28
Thalys Medical Technology Group Corporation to Report Q1, 2024 Results on Apr 27, 2024 Mar 29 An undisclosed buyer acquired 51% stake in Shanxi Thalys Medical Technology Co., Ltd. from Thalys Medical Technology Group Corporation (SHSE:603716) for CNY 1.53 million.
Thalys Medical Technology Group Corporation (SHSE:603716) announces an Equity Buyback for CNY 20 million worth of its shares. Feb 08
Thalys Medical Technology Group Corporation to Report Fiscal Year 2023 Results on Apr 27, 2024 Dec 29
New major risk - Financial position Oct 27
Second quarter 2023 earnings released: EPS: CN¥0.084 (vs CN¥0.099 loss in 2Q 2022) Aug 30
New minor risk - Share price stability Aug 10
Thalys Medical Technology Group Corporation to Report First Half, 2023 Results on Aug 30, 2023 Jun 28
First quarter 2023 earnings released: CN¥0.07 loss per share (vs CN¥0.10 profit in 1Q 2022) Apr 28
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: CN¥0.016 loss per share (vs CN¥0.012 loss in 3Q 2021) Oct 27
Second quarter 2022 earnings released: CN¥0.099 loss per share (vs CN¥0.012 loss in 2Q 2021) Aug 17
Huang Jianfeng completed the acquisition of Thalys Medical Technology Group Inc. (SHSE:603716) from Saihai (Shanghai) Health Technology Co., Ltd. Aug 12
Full year 2021 earnings: EPS and revenues exceed analyst expectations Apr 27
Less than half of directors are independent Apr 27
Second quarter 2021 earnings released: CN¥0.012 loss per share (vs CN¥0.18 profit in 2Q 2020) Aug 25
Investor sentiment improved over the past week Jun 05
First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.12 loss in 1Q 2020) Apr 30
New 90-day low: CN¥14.45 Feb 03
New 90-day low: CN¥14.50 Jan 14
New 90-day high: CN¥17.71 Dec 16
New 90-day low: CN¥14.70 Nov 02
Third quarter earnings released Oct 30
Thalys Medical Technology Group Inc. to Report Q3, 2020 Results on Oct 30, 2020 Oct 29
New 90-day high - CN¥18.10 Sep 14
First half earnings released Aug 21
Thalys Medical Technology Inc. (SHSE:603716) agreed to acquire remaining 49% stake in Shanghai Thalys Medical Technology Co., Ltd. from Liu Hongkui and Zhang Luqi for CNY 0. Aug 06
New 90-day high - CN¥17.33 Jul 29 Aktionärsrenditen 603716 CN Biotechs CN Markt 7D 15.4% 6.9% 6.9% 1Y -28.2% -11.4% 10.3%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: 603716 unter dem Niveau der Branche CN Biotechs , die im vergangenen Jahr eine Rendite von -11.4% erzielte.
Rendite vs. Markt: 603716 hinter dem Markt CN zurück, der im vergangenen Jahr eine Rendite von 10.3 erzielte.
Preisvolatilität Is 603716's price volatile compared to industry and market? 603716 volatility 603716 Average Weekly Movement 8.2% Biotechs Industry Average Movement 8.7% Market Average Movement 7.9% 10% most volatile stocks in CN Market 12.2% 10% least volatile stocks in CN Market 5.4%
Stabiler Aktienkurs: 603716 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.
Volatilität im Zeitverlauf: 603716Die wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen Die Thalys Medical Technology Group Corporation bietet intensive Dienstleistungen im Bereich der medizinischen Inspektion in China an. Das Unternehmen war früher als Thalys Medical Technology Inc. bekannt und änderte im September 2020 seinen Namen in Thalys Medical Technology Group Inc. Die Thalys Medical Technology Group Inc. wurde 2004 gegründet und hat ihren Hauptsitz in Wuhan, China.
Mehr anzeigen Thalys Medical Technology Group Corporation's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Thalys Medical Technology Group im Vergleich zum Marktanteil des Unternehmens? 603716 grundlegende Statistiken Marktanteil CN¥1.58b Gewinn(TTM ) -CN¥210.78m Umsatz(TTM ) CN¥1.90b
0.8x Kurs-Umsatz-Verhältnis
-7.5x Kurs-Gewinn-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) 603716 Gewinn- und Verlustrechnung (TTM ) Einnahmen CN¥1.90b Kosten der Einnahmen CN¥1.54b Bruttogewinn CN¥357.14m Sonstige Ausgaben CN¥567.92m Umsatz -CN¥210.78m
Zuletzt gemeldete Gewinne
Sep 30, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) -1.13 Bruttomarge 18.83% Nettogewinnspanne -11.11% Schulden/Eigenkapital-Verhältnis 96.1%
Wie hat sich 603716 auf lange Sicht entwickelt?
Historische Performance und Vergleiche
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
